Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why AstraZeneca’s Olaparib Setback Could Be A Bigger Deal Than It Is

This article was originally published in The Pink Sheet Daily

Executive Summary

Investors don’t have enormous expectations for olaparib in the small subset of ovarian cancer patients AstraZeneca was targeting for accelerated approval, but the negative FDA advisory committee review comes at a pivotal time for the company.

You may also be interested in...



BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back

With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.

Pfizer’s Biosimilar Strategy Might Be Working

Pfizer's biosimilar franchise  is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.

Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions

The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel